These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 29885519)

  • 21. Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E.
    Zhang Y; Pusch S; Innes J; Sidlauskas K; Ellis M; Lau J; El-Hassan T; Aley N; Launchbury F; Richard-Loendt A; deBoer J; Chen S; Wang L; von Deimling A; Li N; Brandner S
    Cancer Res; 2019 Oct; 79(19):4994-5007. PubMed ID: 31391185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas.
    Mo H; Magaki S; Deisch JK; Raghavan R
    J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy.
    Krell A; Wolter M; Stojcheva N; Hertler C; Liesenberg F; Zapatka M; Weller M; Malzkorn B; Reifenberger G
    Neuropathol Appl Neurobiol; 2019 Aug; 45(5):441-458. PubMed ID: 30548945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
    Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
    J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
    Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
    Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High levels of TIMP1 are associated with increased extracellular matrix stiffness in isocitrate dehydrogenase 1-wild type gliomas.
    Luo CH; Shi Y; Liu YQ; Liu Q; Mao M; Luo M; Yang KD; Wang WY; Chen C; Niu Q; Yan ZX; Miao JY; Zhang XN; Zeng H; Li L; Bian XW; Ping YF
    Lab Invest; 2022 Dec; 102(12):1304-1313. PubMed ID: 35882906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
    Schliesser MG; Claus R; Hielscher T; Grimm C; Weichenhan D; Blaes J; Wiestler B; Hau P; Schramm J; Sahm F; Weiß EK; Weiler M; Baer C; Schmidt-Graf F; Schackert G; Westphal M; Hertenstein A; Roth P; Galldiks N; Hartmann C; Pietsch T; Felsberg J; Reifenberger G; Sabel MC; Winkler F; von Deimling A; Meisner C; Vajkoczy P; Platten M; Weller M; Plass C; Wick W
    Oncotarget; 2016 Dec; 7(50):82028-82045. PubMed ID: 27880937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-424 functions as a tumor suppressor in glioma cells and is down-regulated by DNA methylation.
    Jin C; Li M; Ouyang Y; Tan Z; Jiang Y
    J Neurooncol; 2017 Jun; 133(2):247-255. PubMed ID: 28508328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma.
    Zhang H; Zhang L; Tang Y; Wang C; Chen Y; Shu J; Zhang K
    Biomed Pharmacother; 2019 Oct; 118():109215. PubMed ID: 31545245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
    Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association between
    Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
    Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers.
    Unruh D; Zewde M; Buss A; Drumm MR; Tran AN; Scholtens DM; Horbinski C
    Sci Rep; 2019 Jun; 9(1):8946. PubMed ID: 31222125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
    Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
    Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
    Christensen BC; Smith AA; Zheng S; Koestler DC; Houseman EA; Marsit CJ; Wiemels JL; Nelson HH; Karagas MR; Wrensch MR; Kelsey KT; Wiencke JK
    J Natl Cancer Inst; 2011 Jan; 103(2):143-53. PubMed ID: 21163902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations.
    Cui D; Sajan P; Shi J; Shen Y; Wang K; Deng X; Zhou L; Hu P; Gao L
    Oncotarget; 2017 Apr; 8(15):25345-25361. PubMed ID: 28445981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-320a functions as a suppressor for gliomas by targeting SND1 and β-catenin, and predicts the prognosis of patients.
    Li H; Yu L; Liu J; Bian X; Shi C; Sun C; Zhou X; Wen Y; Hua D; Zhao S; Ren L; An T; Luo W; Wang Q; Yu S
    Oncotarget; 2017 Mar; 8(12):19723-19737. PubMed ID: 28160566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.